Article Text

Download PDFPDF
Randomised controlled trial
Uplifting results of tiotropium in moderate COPD (GOLD stage 2)
  1. Huib A M Kerstjens,
  2. N H T ten Hacken
  1. Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, The Netherlands
  1. Correspondence to Professor Huib A M Kerstjens
    Head of Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, Post Box 30.001, 9700RB Groningen, The Netherlands; h.a.m.kerstjens{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:

For a long time, many doctors have had a relatively nihilistic approach to patients with chronic obstructive pulmonary disease (COPD). The disease was deemed self-inflicted (smoking) and relentlessly progressive, and the available interventions made little difference. Are these notions (still) correct?

It is now known that the disease can also be acquired without smoking—including as a result of outdoor and indoor air pollution (biomass cooking and heating), especially in third world countries.1 It is also known that stopping smoking completely reverses decline in lung function to pretty much the levels of non-smokers.2 Finally—and perhaps most importantly—doctors can now make a difference to patients, although they sometimes fail to do so. It does require a proper perspective on what matters to the patient, as opposed to some measure of lung function such as the forced expiratory volume (FEV1). Patients talk about limited physical capacity, exacerbations, quality of life (QOL) and mortality, not about their lung function. Level …

View Full Text


  • Competing interests HAMK has acted as a consultant and investigator for Boehringer, the manufacturer of tiotropium.